diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM7949diaendo-7949Research ArticleДиагностика, контроль, лечениеDiagnosis, control, treatmentСравнительный анализ качества жизни пациентов на канаглифлозине и ингибиторе дипептидилпептидазы IVComparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitorhttps://orcid.org/0000-0001-9390-1200ПетунинаНина АлександровнаPetuninaNina A.

Д.м.н., профессор, зав. кафедры эндокринологии ИПО Первого МГМУ им.И.М.Сеченова

napetunina@mail.ruТереховаАнна ЛеонтьевнаTerekhovaAnna L.

ассистент кафедры эндокринологии ИПО Первого МГМУ им.И.М.Сеченова

tepexova@mail.ruГончароваЕкатерина ВалерьевнаGoncharovaEkaterina V.

ассистент кафедры эндокринологии ИПО Первого МГМУ им.И.М.Сеченова

goncharova_ev@list.ruФГБОУ ВО Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияSechenov First Moscow State Medical UniversityRussian Federation201602122016196511517Copyright © Петунина Н.А., Терехова А.Л., Гончарова Е.В., 20162016Петунина Н.А., Терехова А.Л., Гончарова Е.В.Petunina N.A., Terekhova A.L., Goncharova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7949

В настоящей работе с позиций индивидуализированного подхода обсуждаются возможности применения канаглифлозина в терапии сахарного диабета 2 типа (СД2). В центре внимания – результаты 52-недельного двойного слепого активно-контролируемого исследования, которые продемонстрировали основанную на значимом снижении массы тела способность канаглифлозина улучшать качество жизни и повышать удовлетворенность физическим и эмоциональным здоровьем у пациентов с диабетом в сравнении с препаратом из группы ингибиторов дипептидилпептидазы IV – ситаглиптином.

The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.

ингибиторы натрий-глюкозного ко-транспортераканаглифлозинситаглиптинкачество жизниассоциированное с весомвлияние веса на качество жизниопросник для оценки удовлетворенности состоянием здоровьяSGLT-2 inhibitorscanagliflozinsitagliptinHealth Related Quality of Life (HRQoL)Impact of Weight on Quality of Life-Lite (IWQOL-Lite)Current Health Satisfaction Questionnaire (CHES-Q)компания ЯнссенReferencesWilliamson DA, Rejeski J, Lang W, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163-171. doi: 10.1001/archinternmed.2008.544Williamson DA, Rejeski J, Lang W, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163-171. doi: 10.1001/archinternmed.2008.544Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(10):882-892. doi: 10.1111/j.1463-1326.2012.01595.xDavies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(10):882-892. doi: 10.1111/j.1463-1326.2012.01595.xPi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94-107. doi: 10.3810/pgm.2009.09.2056Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94-107. doi: 10.3810/pgm.2009.09.2056Proper KI. Short term effect of feedback on fitness and health measurements on self reported appraisal of the stage of change. Br J Sports Med. 2003;37(6):529-534. doi: 10.1136/bjsm.37.6.529Proper KI. Short term effect of feedback on fitness and health measurements on self reported appraisal of the stage of change. Br J Sports Med. 2003;37(6):529-534. doi: 10.1136/bjsm.37.6.529Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev. 2001;2(3):173-182. doi: 10.1046/j.1467-789x.2001.00032.xFontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev. 2001;2(3):173-182. doi: 10.1046/j.1467-789x.2001.00032.xGrandy S, Fox KM, Bazata DD. Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study. Cardiol Res Pract. 2012;2012:892564. doi: 10.1155/2012/892564Grandy S, Fox KM, Bazata DD. Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study. Cardiol Res Pract. 2012;2012:892564. doi: 10.1155/2012/892564Fine JT. A Prospective Study of Weight Change and Health-Related Quality of Life in Women. Jama. 1999;282(22):2136. doi: 10.1001/jama.282.22.2136Fine JT. A Prospective Study of Weight Change and Health-Related Quality of Life in Women. Jama. 1999;282(22):2136. doi: 10.1001/jama.282.22.2136Kroenke CH, Kubzansky LD, Adler N, Kawachi I. Prospective change in health-related quality of life and subsequent mortality among middle-aged and older women. Am J Public Health. 2008;98(11):2085-2091. doi: 10.2105/AJPH.2007.114041Kroenke CH, Kubzansky LD, Adler N, Kawachi I. Prospective change in health-related quality of life and subsequent mortality among middle-aged and older women. Am J Public Health. 2008;98(11):2085-2091. doi: 10.2105/AJPH.2007.114041Blake CE, Hebert JR, Lee DC, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371. doi: 10.1155/2013/291371Blake CE, Hebert JR, Lee DC, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371. doi: 10.1155/2013/291371Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592. doi: 10.1007/s00125-013-3039-1Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592. doi: 10.1007/s00125-013-3039-1Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382(9896):941-950. doi: 10.1016/s0140-6736(13)60683-2Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382(9896):941-950. doi: 10.1016/s0140-6736(13)60683-2Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-2515. doi: 10.2337/dc12-2491Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-2515. doi: 10.2337/dc12-2491Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37. doi: 10.1186/1472-6823-14-37Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37. doi: 10.1186/1472-6823-14-37Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163-175. doi: 10.1185/03007995.2013.850066Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163-175. doi: 10.1185/03007995.2013.850066Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-477. doi: 10.1111/dom.12273Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-477. doi: 10.1111/dom.12273Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41(2):72-84. doi: 10.3810/hp.2013.04.1020Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41(2):72-84. doi: 10.3810/hp.2013.04.1020Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438-444. doi: 10.1016/j.jdiacomp.2014.12.016Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438-444. doi: 10.1016/j.jdiacomp.2014.12.016Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-411. doi: 10.2337/dc14-1237Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-411. doi: 10.2337/dc14-1237Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70(10):1149-1158. doi: 10.1007/s00228-014-1730-xYang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70(10):1149-1158. doi: 10.1007/s00228-014-1730-xWilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267-1282. doi: 10.1111/ijcp.12322Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267-1282. doi: 10.1111/ijcp.12322Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473. doi: 10.1111/dom.12090Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473. doi: 10.1111/dom.12090Schernthaner G, Gross J, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-2515. Diabetes Care. 2013;36(12):4172-4172. doi: 10.2337/dc13-er12aSchernthaner G, Gross J, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-2515. Diabetes Care. 2013;36(12):4172-4172. doi: 10.2337/dc13-er12aTraina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126(3):7-15. doi: 10.3810/pgm.2014.05.2752Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126(3):7-15. doi: 10.3810/pgm.2014.05.2752Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153-1160. doi: 10.1016/j.jclinepi.2004.04.004Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153-1160. doi: 10.1016/j.jclinepi.2004.04.004

The authors declare that there are no conflicts of interest present.